🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are escalating around the world, with data suggesting in excess of 82 million infections per year. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is also used to treat UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization represents a significant shift in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Results and Worldwide Availability

As per data detailed in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses a dual-drug approach. The trial enrolled over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the authority to register and commercialise the drug in a wide range of developing nations.

Doctors on the front lines have shared optimism. The availability of a single-dose, oral treatment such as this is seen as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the infection for people and to prevent the spread of untreatable gonorrhoea worldwide.